Chongqing-based pharmaceutical holding company selling drugs and health products in China.
Chongqing-based pharmaceutical holding company selling drugs and health products in China.
Moat: none
Headquarters: Chongqing, China · Employees: 12,237
Size C.Q. Pharmaceutical (000950.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.24B, the 1796th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.88 on 18 Nov 2026.
Performance Over six months the shares fell 26.9%, against -16.4% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 3.1% over the last twelve months (peer median +5.3%); the operating margin is 0.8% (peer median -2.0%).
Valuation It trades at 18.6× forward earnings against a peer median of 24.0× (5th cheapest of 11).
Capital Return on invested capital runs 3.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥80.5B | CN¥82.3B | CN¥80.5B | CN¥78.3B | CN¥67.7B |
| Revenue growth | — | +2% | +3% | +16% | — |
| Gross profit | CN¥5.62B | CN¥5.40B | CN¥5.47B | CN¥5.73B | CN¥5.36B |
| EBITDA | n/a | CN¥1.54B | CN¥1.78B | CN¥2.35B | CN¥2.64B |
| Net income | CN¥323M | CN¥387M | CN¥283M | CN¥625M | CN¥952M |
| Free cash flow | -CN¥501M | CN¥544M | -CN¥371M | CN¥300M | CN¥40.9M |
| Capital expenditure | CN¥328M | CN¥300M | CN¥251M | CN¥244M | CN¥268M |
| Total debt | CN¥29.7B | CN¥28.1B | CN¥28.9B | CN¥27.2B | CN¥27.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000950.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -5.4% | 10th highest of 21 |
| 6-month return | -26.9% | -16.4% | 6th lowest of 21 |
| Distance from 52-week high | -34.1% | -41.7% | 7th highest of 21 |
| Revenue growth (TTM) | -3.1% | +5.3% | 7th lowest of 17 |
| Operating margin | 0.8% | -2.0% | 7th highest of 17 |
| Forward P/E | 18.6× | 24.0× | 5th cheapest of 11 |
| ROIC minus cost of capital | -3.3 pp | -6.1 pp | 5th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |